Research examining Oregon’s nonmedical psilocybin program, the first regulated psychedelic service model in the United States, has produced largely favorable findings regarding both safety and participant satisfaction. The analysis, published in JAMA Network Open, drew data from approximately 350 individuals who accessed psilocybin at state-licensed facilities. Participants reported their experiences as predominantly beneficial, with more than half identifying their sessions among the most meaningful experiences of their lives.
The program was established following voter approval in 2020, allowing adults over 21 to use psilocybin under facilitator supervision at designated centers without requiring a medical prescription or referral. Since its launch approximately three years ago, more than 20,000 people have participated. The average administered dose was about 30 milligrams. Participants cited various motivations for participation, with curiosity, self-improvement, mental health concerns, and trauma being the most frequently mentioned reasons.
Safety outcomes were generally reassuring, with only a very small number of participants experiencing serious adverse reactions. Most reported issues were behavioral rather than physical in nature. Notable incidents included one person hospitalized following a violent reaction and another requiring emergency care due to anxiety. The four individuals classified as having serious adverse reactions were all trying psilocybin for the first time. Within one week of their session, three participants reported new thoughts of dying or suicide, a number that doubled by the three-month follow-up point.
Researchers noted certain limitations to the study’s generalizability. Participants were predominantly white and college-educated, with approximately one-third reporting household incomes exceeding $200,000. These demographics reflected the broader population accessing the licensed centers, which are primarily concentrated in the Portland area. Some experts cautioned that the reported safety profile may not extend universally, citing concerns that study participants may represent a self-selected group and suggesting that adverse events could be underreported.
The research represents a distinct pathway from traditional drug development trials seeking Food and Drug Administration approval for psilocybin as a psychiatric treatment. Investigators indicated plans to expand the study through a larger research initiative called the Open Psychedelic Evaluation Nexus, or OPEN, to track a substantially larger sample of participants.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI